Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
189 studies found for:    "Nerve sheath neoplasm"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Terminated Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas
Condition: Neurofibroma
Intervention: Drug: LS11
2 Unknown  First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Condition: Cutaneous Neurofibromas
Intervention: Procedure: Erbium-YAG laser vaporization
3 Active, not recruiting Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   Neurofibromas
Intervention: Drug: Gleevec
4 Active, not recruiting Study of PEG-Intron for Plexiform Neurofibromas
Condition: Plexiform Neurofibroma
Intervention: Drug: PEG-Intron
5 Terminated Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Condition: Malignant Peripheral Nerve Sheath Tumors
Intervention: Drug: imatinib mesylate
6 Recruiting Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Intervention: Drug: Imatinib Mesylate
7 Terminated
Has Results
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Intervention: Drug: Everolimus (RAD001)
8 Completed Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Ranibizumab
9 Recruiting A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Condition: Malignant Peripheral Nerve Sheath Tumour (MPNST)
Intervention: Drug: Pembrolizumab
10 Completed Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Conditions: Neurofibromas;   Neurofibromatosis Type 1
Intervention:
11 Completed Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Imiquimod 5% Cream
12 Completed
Has Results
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Conditions: Neurofibroma, Plexiform;   Neurofibromatosis Type I
Interventions: Drug: tipifarnib;   Other: placebo
13 Completed Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Conditions: Neurofibromatosis Type I;   Plexiform Neurofibroma
Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity
14 Completed
Has Results
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Conditions: Neurofibromatosis 1;   Neurofibroma, Plexiform
Intervention: Drug: Pirfenidone
15 Active, not recruiting Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Neurofibromas
Intervention: Drug: Tasigna
16 Recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
17 Recruiting Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Conditions: Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:
18 Recruiting Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Conditions: Cutaneous Neurofibromas;   Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Procedure: Skin Biopsy
19 Suspended
Has Results
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Plexiform Neurofibromas
Intervention: Drug: Sutent®/Sunitinib
20 Active, not recruiting
Has Results
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma;   Spinal Cord Neurofibroma
Intervention: Drug: Cediranib Maleate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.